Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Clinical Cooperation Unit Nuclear Medicine

Prof. Dr. Uwe Haberkorn (in ch.)

DOTATOC-PET in a patient with metastasized neuroendocrine tumor.

The Clinical Cooperation Unit (CCU) Nuclear Medicine is involved in multiple projects such as the planning and follow up of chemo- or radiation therapy, pharmacokinetic modeling of dynamic PET data, identification of new peptides with high affinity for tumor disease; the establishment of new endoradiotherapy approaches based on peptides and antibodies; the development of alternate panning strategies with phage and ribosome display using recombinant proteins, membrane fractions and cells; the design of combination therapy with endoradiotherapy and chemo-, immuno- or radiation therapy; and the establishment of new treatments for non-iodine-concentrating thyroid carcinoma.

One major topic for the CCU Nuclear Medicine’s future research will be the identification of possible targets for new radiopharmaceuticals. For this purpose, the gene array data obtained from correlative PET and tumor specimen evaluations are screened for receptors and cell surface proteins. Following the identification of possible targets, the partners at the MPI Saarbrücken are using their FLEXx software, a small molecule docking software, to identify substances with a high likelihood of binding to the identified structures.
The identification of new ligands will be one of the main areas of research in the laboratory. The group intends to apply biotechnology methods such as display (phage and ribosome display) of libraries consisting of scaffold proteins. This project addresses the identification of specific binders to targets overexpressed in a variety of tumors by using peptide libraries. We will concentrate on target structures identified either by literature research or by gene profiling data available at the campus. In the last 18 months we have started intra-arterial therapy with DOTATOC in patients with metastasized neuroendocrine tumors using 90Y, 177Lu and 213Bi. This program will be extended to other peptides/receptors. Furthermore, novel treatment strategies using radiolabeled benzamides in melanoma patients and PSMA ligands in patients with prostate carcinoma have been successfully transferred into clinical application.


Prof. Dr. Uwe Haberkorn (in ch.)
Nuclear Medicine (E060)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg
Tel: +49 6221 42 2477
Fax: +49 6221 42 2510

Selected Publications

  • Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. John L, Poos AM, Brobeil A, Schinke C, Huhn S, Prokoph N, Lutz R, Wagner B, Zangari M, Tirier SM, Mallm JP, Schumacher S, Vonficht D, Solé-Boldo L, Quick S, Steiger S, Przybilla MJ, Bauer K, Baumann A, Hemmer S, Rehnitz C, Lückerath C, Sachpekidis C, Mechtersheimer G, Haberkorn U, Dimitrakopoulou-Strauss A, Reichert P, Barlogie B, Müller-Tidow C, Goldschmidt H, Hillengass J, Rasche L, Haas SF, van Rhee F, Rippe K, Raab MS, Sauer S, Weinhold N. Nat Commun. 2023 Aug 17;14(1):5011.
  • Application of an artificial intelligence-based tool in [18F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma. Sachpekidis C, Enqvist O, Ulén J, Kopp-Schneider A, Pan L, Jauch A, Hajiyianni M, John L, Weinhold N, Sauer S, Goldschmidt H, Edenbrandt L, Dimitrakopoulou-Strauss A. Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3697-3708.
  • Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, Sachpekidis C, Humbert O, Gheysens O, Glaudemans AWJM, Weber W, Wahl RL, Scott AM, Pandit-Taskar N, Aide N. Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2323-2341.
  • Kratochwil C. et al. (2010). Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC-PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res, 16(10), 2899–2905.
to top
powered by webEdition CMS